Risk assessment for osteoporosis II: Biochemical markers of bone turnover- Bone resorption indices

Clinics in Laboratory Medicine

Volumn 20, Issue 3, 2000, Pages 503-525

  Woitge, H W ^a   Seibel, M J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN;

BONE ATROPHY; BONE MATRIX; COLLAGEN DEGRADATION; FRACTURE; HIGH RISK PATIENT; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0033846039     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0272-2712(18)30050-7     Document Type: Review

References (106)

1. Antiresorptive effect of a single infusion of microgram quantifies of zoledronate in Paget's disease of bone
2. An optimized continuous-monitoring procedure for semiautomated determination of serum acid phosphatase activity
3. Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared
4. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography
5. Prediction of bone loss in postmenopausal women
6. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen
7. Immunoassay for quantifying type I collagen degradation products in urine evaluated
8. Validation of local and systemic markers of bone turnover
9. Localization of bone sialoprotein (BSP) expression to sites of mineralized tissue formation in fetal rat tissues by in situ hybridization
10. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density
11. Immunoassay of a tartrate-resistant acid phosphatase in serum
12. Increased bone resorption and decreased bone formation in Chinese patients with hip fracture
13. Prediction of rapid bone loss in postmenopausal women
14. Screening procedure for women at risk of developing postmenopausal osteoporosis
15. Bone turnover in postmenopausal osteoporosis Effect of calcitonin treatment
16. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption
17. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease
18. Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption
19. Bone density change and biochemical indices of skeletal turnover
20. Appendicular bone density and age predict hip fracture in women
21. The isolation of identical hydroxylysyl glycosides from hydroxylates of soluble collagen and from human urine
22. Estimation of whole body bone resorption rate: A comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis
23. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease
24. Biochemical markers of bone turnover reflect femoral bone loss in elderly women
25. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption
26. Bone turnover markers and bone density across the menopausal transition
27. Hip and calcaneal bone loss increase with advancing age: Longitudinal results from the study of osteoporotic fractures
28. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues
29. Integrins and factor H mediate bone sialoprotein's and osteopontin's protective properties in complement attack on susceptible cancer cells
30. Postoophorectomy bone loss is associated with reduced bone Gla protein serum levels: A possible effect of osteoblastic insufficiency
31. Matrix sialoprotein of developing bone
32. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region
33. The structure of pyridinoline, a collagen crosslink
34. Differences in composition of cell-attachment sialoproteins between dentin and bone
35. Further characterization of interaction between bone sialoprotein (BSP) and collagen
36. The predictive value of bone loss for fragility fractures in women: A longitudinal study over 15 years
37. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
38. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
39. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study
40. Monoclonal antibody assay for free urinary pyridinium cross-links
41. Collagen cross-linking compounds in human urine
42. Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies
43. Response of biochemical markers of bone turnover to hormone replacement therapy Impact of biological variability
44. Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women
45. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
46. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: The effect of nandrolone decanoate and hormone replacement therapy
47. Structure and biology of cartilage and bone matrix noncollageneous macromolecules
48. The contribution of bone loss to postmenopausal osteoporosis
49. Automated on-line solid-phase extraction and high-performance liquid chromatographic analysis of total and free pyridinium crosslinks in serum
50. Plasma BGP: An indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women
51. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report
52. The diagnosis of osteoporosis
53. Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay
54. Can biochemical markers predict bone loss at the hip and spine? A 4-year prospective study of 141 early postmenopausal women
55. Urinary excretion of hydroxyproline in health and disease
56. Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase
57. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects and osteoporosis patients
58. Immunological and biochemical evidence for identity of tartrate-resistant isoenzymes of acid phosphatases from human serum and tissues
59. Enzyme immunoassay for tartrate-resistant acid phosphatase
60. Characterization and assay of tartrate-resistant acid phosphatase activity in serum: Potential use to assess bone resorption
61. Biological variability of serum immunoreactive bone sialoprotein
62. Urinary galactosyl-hydroxylysine in postmenopausal osteoporotic women: A potential marker of bone fragility
63. Hydroxyproline metabolism by the rat kidney: Distribution of renal enzymes of hydroxyproline catabolism and renal conversion of hydroxyproline to glycine and serine
64. Relationship of bone fractures to bone density and fractures
65. Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function
66. Estimation of bone mineral density and bone loss by means of bone metabolic markers in postmenopausal women
67. Can urinary pyridinium crosslinks and urinary estrogens predict bone mass and rate of bone loss after the menopause?
68. Determination of galactosyl hydroxylysine in urine as a means for the identification of osteoporotic women
69. High-performance liquid chromatographic analysis of urinary hydroxylysyl glycosides as indicators of collagen turnover
70. Urinary beta-1-galactosyl-0-hydroxylysine (GH) as a marker of collagen turnover of bone
71. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers
72. A novel fluor in insoluble collagen: A crosslinking moiety in collagen molecule
73. Age-related structural changes in trabecular and cortical bone: Cellular mechanisms and biomechanical consequences
74. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis
75. Automated analysis of the pyridinium cross-links of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography
76. The biosynthesis of collagen and its disorders
77. High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women
78. Evolution of spinal bone loss and biochemical markers of bone remodeling after menopause in normal women
79. Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy
80. Low bone mass and fast rate of bone loss at menopause Equal risk factors for future fracture: A 15-year follow-up study
81. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy
82. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation
83. Fibrillogenesis and maturation of collagens
84. Turnover of collagen and its precursors
85. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption
86. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
87. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption
88. Rapid bone loss is associated with increased levels of biochemical markers
89. Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis
90. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women
91. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density
92. Which fractures are associated with low appendicular bone mass in elderly women?
93. Variations in human urinary O-hydroxylysyl glycoside levels and their relationship to collagen metabolism
94. Urinary hydroxy-pyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis
95. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease
96. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis Results of a pilot study
97. Immunoassay for urinary pyridinoline: The new marker of bone resorption
98. Characterization of porcine bone sialoprotein: Primary structure and cellular expression
99. Biochemical parameters associated with low bone density in healthy men and women
100. Collagen and disorders of bone
101. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women
102. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks
103. Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study
104. Which fractures are associated with high bone resorption in elderly women: The Rotterdam study
105. Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices
106. Seasonal variation of biochemical indexes of bone turnover: Results of a population-based study